Pacira Pharma (PCRX) Tops Q1 EPS by 3c ; Offers Guidance

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $168.92 million versus the consensus estimate of $175.6 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $725-765 million, versus the consensus of $752.9 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance